Economics of anti-rhesus prophylaxis in an African population.
D003362:Cost-Benefit Analysis; D004899:Erythroblastosis, Fetal / Q000453:epidemiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007116:Immunization, Passive / Q000191:economics*; D007231:Infant, Newborn; D007518:Isoantibodies; D011247:Pregnancy; D011446:Prospective Studies; D012189:Retrospective Studies; D012203:Rh Isoimmunization / Q000453:epidemiology / Q000517:prevention & control*; D012204:Rh-Hr Blood-Group System / Q000276:immunology; D015030:Zimbabwe
D007518:Isoantibodies; C033242:RH-antibodies; D012204:Rh-Hr Blood-Group System